Skip to main content

Table 1 Baseline characteristics of study cohort

From: Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China

Variable All patients (n = 1208) Surgery Nonsurgery (n = 480)
curative (n = 380) Palliative (n = 348)
Age (median) 63 61 63 64
Gender (male) 736 (60.9 %) 232 (61.1 %) 248 (71.3 %) 256 (53.3 %)
Smoking (yes) 448 (37.1 %) 148 (38.9 %) 160 (46.0 %) 140 (29.2 %)
Diabetes (yes v no) 256 (21.2 %) 52 (13.7 %) 96 (27.6 %) 116 (24.2 %)
Alcoholism (yes v no) 256 (21.2 %) 80 (21.1 %) 96 (27.6 %) 80 (16.7 %)
Chief complaint
 No symptom 120 (9.9 %) 68 (17.9 %) 8 (2.3 %) 44 (9.2 %)
 Abdominal distention/pain 664 (55 %) 172 (45.3 %) 184 (52.9 %) 308 (64.2 %)
 Jaundice 360 (29.8 %) 128 (33.7 %) 148 (42.5 %) 84 (17.5 %)
 Weight loss 64 (5.3 %) 12 (3.2 %) 8 (2.3 %) 44 (9.2 %)
Tumor characteristics
 Tumor size (≤2) 192 (15.9 %) 80 (21.1 %) 56 (16.1 %) 56 (11.7 %)
 Tumor number (single) 1176 (97.4 %) 364 (95.8 %) 340 (97.7 %) 472 (98.3 %)
 Tumor encapsulation (yes) 284 (74.7 %) 212 (60.9 %)
 Tumor location (head) 856 (70.9 %) 284 (74.7 %) 340 (97.7 %) 232 (48.3 %)
 Tumor differentiation (I–II) 276 (72.6 %) 148 (42.5 %)
 Lymph nodes positive (yes) 84 (22.1 %) 96 (27.6 %)
 AJCC stage (I–II) 512 (42.4 %) 300 (78.9 %) 136 (39.1 %) 76 (15.8 %)
CEA (≤2ULN) 924 (76.5 %) 296 (77.9 %) 292 (83.9 %) 336 (70.0 %)
CA19-9 (≤2ULN)k 316 (26.2 %) 164 (43.2 %) 72 (20.1 %) 80 (16.7 %)
Chemotherapy (yes) 892 (73.8 %) 324 (85.3 %) 308 (88.5 %) 260 (54.2 %)
  1. Tumor differentiation: I, Well differentiated; II, moderately differentiated; III, poorly differentiated; and IV, undifferentiated
  2. AJCC American Joint Committee on Cancer staging system, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9. ULN Upper Limit of Normal. ULN of CEA and CA19-9 are 10 ng/ml and 22U/ml